

# Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

LINGYUN YANG, NINGWEI LI, HONGJING WANG, XIBIAO JIA, XUE WANG and JUAN LUO

Department of Gynecology and Obstetrics, West China Second University Hospital,  
Sichuan University, Chengdu, Sichuan 610041, P.R. China

Received February 7, 2012; Accepted April 2, 2012

DOI: 10.3892/or.2012.1823

**Abstract.** microRNAs (miRNAs) are short non-coding RNA molecules which are involved in the regulation of various biological processes. Drug resistance has become a major obstacle to successful chemotherapy of ovarian cancer. The aim of this study was to investigate microRNA expression profiles in cisplatin-resistant ovarian cancer cells and the role of miR-130a in regulating drug resistance. Analysis of differentially expressed miRNAs between SKOV3 and SKOV3/CIS cells was assessed by miRNA microarrays. Target prediction of miRNAs was determined with the help of PicTar or TargetScan. Among these miRNAs, the expression of miR-130a was verified using qRT-PCR. The expression of MDR1 mRNA and P-glycoprotein (P-gp) after cellular transfection was examined using qRT-PCR and western blotting, respectively. Cisplatin sensitivity was detected by the MTT assay. We identified 35 downregulated and 54 upregulated miRNAs in SKOV3/CIS compared to those in SKOV3. We found that miR-130a was upregulated in SKOV3/CIS compared to the parental SKOV3 cells, and PTEN was predicted to be the potential target of miR-130a. Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. This study provides important information for the

development of targeted gene therapy for reversing cisplatin resistance in ovarian cancer.

## Introduction

Ovarian cancer is the deadliest cancer of the female reproductive system (1). More than 70% newly diagnosed patients with ovarian cancer have advanced stage disease (FIGO stage III or IV) because of no early symptoms and effective biomarker screening (2). Primary cytoreduction followed by platinum-based combined chemotherapy, such as cisplatin coupled with paclitaxel, has become the main therapeutic approach for advanced ovarian cancer (3-6). Cisplatin crosslinks to double stranded DNA and forms DNA adducts, interfering with DNA replication and transcription, which in turn activates cellular apoptosis. However, development of a multidrug resistance phenotype is a major obstacle to successful treatment of ovarian cancer, which leads to 85-90% relapse and only 30% 5-year survival rate (6,7). Several molecular mechanisms of drug resistance have been discovered and characterized including the overexpression of MDR1/P-glycoprotein (P-gp) (8,9), increased anti-apoptotic factors activity (8,10,11), altered expression of  $\beta$ -tubulin subunits (12), degeneration of growth factor receptor (13), and increased DNA repair activity (14,15). Drug efflux induced by increased accumulation of various ATP-binding cassette (ABC) transporters, including ABCB1, also known as P-gp, which is a 170-kDa transmembrane glycoprotein encoded by MDR1 gene on human chromosome 7p21, has been demonstrated to play a significant role in drug resistance (8,9,16).

microRNAs (miRNAs) are a class of short non-coding RNA molecules that bind to the 3'-untranslated region (3'-UTR) of the target mRNAs and act post-transcriptionally as negative regulators of gene expression (17-19). Mature miRNAs, derived from precursor miRNA (pre-miRNA), are incorporated into the RNA-induced silencing complex (RISC), resulting in either cleavage or translational repression of target mRNAs (20,21). It has been reported that miRNA-mediated gene regulation plays critical roles in biological processes including cellular proliferation, differentiation, apoptosis, metabolism and oncogenesis (17,22,23). Recent studies show that miRNAs associated with oncogenesis act

---

*Correspondence to:* Professor Hongjing Wang, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Renmin South Road Section 3 No. 17, Chengdu, Sichuan 610041, P.R. China  
E-mail: whjcdx@163.com

**Key words:** ovarian cancer, cisplatin resistance, microRNA, expression profiling, miR-130a

as oncogenes or tumor suppressors. For example, miR-155, upregulated in ovarian and lung cancer, acts as an oncogene (24,25), while miR-15a and miR-16a, deregulated in CLL, act as tumor suppressors (26). In addition, further reports show that miRNAs also play a vital role in chemotherapeutic drug resistance (27-29). Analysis of the up- and downregulation and the mechanism of action of miRNAs may be useful to develop novel plans of targeted therapies.

In the current study, we performed miRNAs expression profile analysis between the human ovarian cancer cell line SKOV3 and the cisplatin-resistant cell line SKOV3/CIS followed by qRT-PCR based validation of miR-130a expression. We also examined the role of miR-130a in the development of cisplatin-resistance in ovarian cancer cells, which may provide a potential target for gene therapy.

## Materials and methods

**Cell culture.** The human ovarian cancer cell line SKOV3 and the cisplatin-resistant cell line SKOV3/CIS were cultured in PRMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator with 5% CO<sub>2</sub> at 37°C. SKOV3/CIS was alternately fed with medium containing 7.5 µg/ml cisplatin and was regularly tested for maintenance of drug-resistance. Growth and morphology of each cell line were observed and monitored every three days. The cisplatin-resistant cell was maintained in drug-free medium for 1 week before follow-up experiments. Both cell lines were preserved in Gynecological Oncology of Biotherapy Laboratory, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.

**miRNA microarray analysis.** Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and the miRNeasy mini kit (Qiagen, Copenhagen, Denmark) according to the manufacturer's instructions, which efficiently covered all RNA species including miRNAs. RNA quality and quantity was measured using the NanoDrop spectrophotometer (ND-1000, NanoDrop Technologies) and RNA integrity was determined by gel electrophoresis. The miRCURY™ Power labeling kit (Exiqon, Vedbaek, Denmark) was used for miRNA labeling. Each sample (1 µg) was 3'-end-labeled with Hy3™ fluorescent label using T4 RNA ligase. Then the Hy3™-labeled samples were hybridized on the miRCURY™ LNA Array (v.16.0, Exiqon), which contained more than 1,891 capture probes, covering all human, mouse and rat miRNAs annotated in miRBase 16.0, as well as all viral miRNAs related to these species. In addition, this array contained capture probes for 66 new miRPlus™ human miRNAs which were proprietary miRNAs not found in miRBase. The total 25-µl mixture from Hy3™-labeled samples with 25 µl hybridization buffer were first denatured for 2 min at 95°C, incubated on ice for 2 min and then hybridized to the microarray for 16-20 h at 56°C in a 12-Bay hybridization systems (NimbleGen Systems, Inc., Madison, WI, USA). Following hybridization, the slides were washed, dried and then scanned using the Axon GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA, USA). Images were then imported into GenePix Pro

6.0 software (Axon) for grid alignment and data extraction. Expressed data were normalized using the median normalization. The normalized fluorescence intensity, which was less than the average intensity of the negative controls or 3x SD of the intensity of the negative controls, indicated an unreliable signal value. After normalization, differentially expressed miRNAs were identified through fold-change filtering. Hierarchical clustering was performed using standard correlation as a measure of similarity by the MEV software (v4.6, TIGR). Three microarray chips were applied for each cell line.

**Bioinformatics.** Target prediction of differentially expressed miRNAs was determined with the help of PicTar (<http://pictar.mdc-berlin.de/>) (30,31) or TargetScan 5.2 (<http://www.targetscan.org/>) (32,33).

**Real-time qRT-PCR for miR-130a.** Verification of altered miR-130a expression was performed in SKOV3 and SKOV3/CIS by real-time qRT-PCR. Total RNA of each cell line was extracted with TRIzol reagent (Invitrogen) and was assessed by agarose gel electrophoresis and spectrophotometry. Complementary DNA (cDNA) was generated using the AMV first strand cDNA synthesis kit (Invitrogen). Specific miR-130a primers and internal control U6 snRNA primers (Bulge-Loop™ miRNA qPCR Primers) were designed and synthesized by Guangzhou RiboBio (Guangzhou RiboBio Co., Ltd., Guangzhou, China). Real-time qRT-PCR was performed in a 20-µl reaction volume containing 2 µl cDNA template, 9 µl SYBR-Green I mix (Takara, China), 2 µl forward primers, 2 µl reverse primer and 5 µl RNase-free H<sub>2</sub>O on the ABI StepOnePlus instrument (Applied Biosystems, USA) using the following protocol: 95°C for 20 sec, followed by 40 cycles of 95°C for 10 sec, 60°C for 20 sec and 70°C for 10 sec. Each sample was run in triplicate. The relative expression of miR-130a was analyzed using 2<sup>-ΔΔCt</sup> method.

**miRNA transfection.** The miR-130a-mimic, -inhibitor and miR-negative RNA were designed and chemically synthesized by Guangzhou RiboBio. Twenty-four hours prior to transfection, SKOV3 and SKOV3/CIS cells were seeded into 6-well plates with 2x10<sup>5</sup> cells/well and cultured in medium without antibiotics. Transfection was performed using Lipofectamine 2000 (Invitrogen) and OPTI-MEM I reduced serum medium (Gibco) according to the manufacturer's instructions. Green fluorescent protein (GFP) was applied to show the efficiency of transfection system. Cells in each well were transfected with 10 µl miR-130a-mimic or -inhibitor or miR-negative RNA or 2 µl GFP constructed plasmid. The medium was replaced 4-6 h after transfection with new fresh medium.

**Real-time qRT-PCR for MDR1 mRNA.** Real-time qRT-PCR was applied to detect the expression of MDR1 mRNA after miRNA transfection for 24 h. Total RNA of each cell line was extracted with TRIzol reagent (Invitrogen) and was assessed by agarose gel electrophoresis and spectrophotometry. Reverse transcription was carried out with the AMV first strand cDNA synthesis kit. The β-actin was used as internal control for MDR1 expression normalization. Primers of MDR1 and β-actin were designed using the Primer Premier software (version 5.0). The primer sequences for real-time qRT-PCR

were: MDR1 (forward) 5'-ACAAAGTGCTCACCCAGATTTC-3' (reverse) 5'-CATTTCTCGCTGATGACACTA-3';  $\beta$ -actin (forward) 5'-GCTACGAGCTGCCTGACG-3' (reverse) 5'-TCGTGGATGCCACAGGAC-3'. Real-time qRT-PCR was performed with cycle parameters as 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 1 min. Each sample was run in triplicate. Data analysis was performed using the  $2^{-\Delta\Delta C_t}$  method.

**Western blot analysis.** Cells were collected and washed twice with ice-cold PBS. Total protein was extracted with RIPA added with 1% protease inhibitor phenylmethanesulfonyl fluoride (PMSF) for 15 min on ice, then centrifuged at 12,000 rpm 4°C for 15 min and the supernatants were collected. Protein concentrations were determined by the BCA method using the standard curve. GAPDH expression was used as internal control. Equal amounts of protein for each sample were resolved using 10% SDS-PAGE gels and transferred onto Immun-Blot™ PVDF membranes (Bio-Rad Laboratories, Hercules, CA, USA). The bands were blocked with a 5% solution of skim dry milk in TBS containing 0.1% Tween-20 for 2 h and incubated with primary antibodies P-gp (diluted 1:1000; Calbiochem, San Diego, CA, USA) and GAPDH (diluted 1:50000; Kangchen, Shanghai, China) overnight at 4°C. After repeated washing three times with TBS-T, membranes were incubated with horseradish peroxidase (HRP) conjugated anti-mouse secondary antibody (Bio-Rad Laboratories) for 2 h. Blots were detected and developed on X-ray film using the chemiluminescence method.

**In vitro drug sensitivity array.** SKOV3 and SKOV3/CIS cells were transfected with miR-130a-mimic or -inhibitor or miR-negative RNA for 24 h, and then transferred into 96-well plates with  $1.5 \times 10^4$  cells/well for a drug sensitivity array. After cellular adhesion, SKOV3 cells were treated with increasing concentrations of cisplatin (0.3, 0.6, 1.2, 2.4, 4.8 and 9.6  $\mu$ g/ml) and SKOV3/CIS were exposed to various doses of cisplatin (3, 6, 12, 24, 48 and 96  $\mu$ g/ml) for 48 h. Following the incubation, 20  $\mu$ l of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, St. Louis, MO, USA) was added to each well and incubated for 4 h. At the end of the incubation, the medium was removed and 150  $\mu$ l DMSO was added. Absorbance of each well was measured at a wavelength of 570 nm using a microplate reader (Model 680, Bio-Rad Laboratories). The  $IC_{50}$  median inhibitory concentration of cisplatin was calculated through a cell viability curve.

**Data and statistical analysis.** Data are presented as the means  $\pm$  standard deviation from at least three replicate experiments. One-way ANOVA was employed to analyze difference of means between groups using SPSS 11.0 software (SPSS Inc., Chicago, IL, USA). Statistical significance was set as  $P < 0.05$ .

## Results

**Profiling of differentially expressed miRNAs in SKOV3 and SKOV3/CIS cells.** RNA quantity and quality of each cell line were assured and checked by spectrophotometer and gel electrophoresis. As shown in Table I, the results confirmed good




Figure 1. Expression of miR-130a and P-gp in SKOV3 and SKOV3/CIS cell lines. (A) The mean fold-change of miR-130a expression was detected by qRT-PCR in SKOV3 and SKOV3/CIS. The relative expression of miR-130a in SKOV3/CIS cells was 24.43-fold higher than that in SKOV3 cells, \* $P < 0.05$ . Each sample was analyzed in triplicate and normalized to U6 snRNA. Fold-change was figured out by  $2^{-\Delta\Delta C_t}$  method. (B) The expression of P-gp, as measured using western blotting, was upregulated in SKOV3/CIS and was absent in SKOV3. GAPDH was used as internal control.

quantity and quality of total RNA isolated from each cell line. To identify the critical miRNAs involved in cisplatin resistance, the microarray platform was applied to profile the global expression of mature miRNA. The signal ratio of SKOV3/CIS to SKOV3 was determined, and the normalized fluorescence intensity, which was less than the average intensity of the negative controls or 3x SD of the intensity of the negative controls indicated an unreliable signal value. Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). Expression of miRNAs in SKOV3/CIS compared to SKOV3 was decreased by 2.02- to 8.23-fold, while increases in expression ranged from 2.02- to 46.74-fold. These results indicated that such differentially expressed miRNAs might play a crucial role in the development of cisplatin resistance in epithelial ovarian cancer. The tumor suppressor PTEN was predicted to be a potential target of miR-130a.

**Expression of miR-130a and P-gp in SKOV3 and SKOV3/CIS.** We performed real-time qRT-PCR for further validation of miR-130a expression level and western blot analysis for comparison of P-gp expression in SKOV3 and SKOV3/CIS cell lines, respectively. High values of relative threshold cycles indicate the low miRNA quantity, which were normalized by U6 snRNA expression, and GAPDH was used as internal

Table I. RNA quantity and quality of each cell line assessed by spectrophotometry.

Cell line	A260/A280 ratio	A260/A230 ratio	Total RNA concentration (ng/ $\mu$ l)	Total RNA amount (ng)
SKOV3	2.01	2.22	1574.25	15742.5
SKOV3/CIS	2.00	2.35	908.09	9080.9

For spectrophotometry, the A260/A280 ratio should be close to 2.0 for pure RNA (ratios between 1.8 and 2.1 are acceptable) and the A260/A230 ratio should be >1.8, which indicates good quantity and quality of total RNA.

Table II. Thirty-five downregulated miRNAs in SKOV3/CIS cell lines and the putative targets.

miRNA ID	Accession no.	Fold-change	Predicted targets
hsa-let-7i*	MIMAT0004585	0.1215	Unknown
hsa-miR-9*	MIMAT0000442	0.1520	Unknown
hsa-miR-630	MIMAT0003299	0.1534	TMED7, FLJ36031, LMO3, TOB2, TFAP2B
hsa-miR-21*	MIMAT0004494	0.1658	Unknown
hsa-miR-205*	MIMAT0009197	0.1715	Unknown
hsa-miR-498	MIMAT0002824	0.2173	TIMM17A, TACSTD1, GRIA3, CREBL2, TP53INP1, ATP2B1
hsa-miR-31	MIMAT0000089	0.2509	RSBN1, PIK3C2A, SLC1A2, PRKCE
hsa-miRPlus-J1011	Unknown	0.2599	Unknown
hsa-miR-210	MIMAT0000267	0.2768	GIT2, ZNF462, FAM116A, KCMF1
hsa-miR-584	MIMAT0003249	0.2826	PRRX1, CADPS, STYX, PHACTR1
hsa-miR-1265	MIMAT0005918	0.2926	BCL-2, IRF2, XPO5
hsa-miR-4308	MIMAT0016861	0.2964	Unknown
hsa-miR-1264	MIMAT0005791	0.2980	ATP2C1, ABCA1, BRCC3, CS, KCNG3, LRRC18
hsa-miR-4324	MIMAT0016876	0.2984	Unknown
hsa-miR-375	MIMAT0000728	0.3045	ITPKB, RASD1, PTPN4, ATP2B3
hsa-miR-3074-3p	MIMAT0015027	0.3345	Unknown
hsa-let-7a-2*	MIMAT0010195	0.3603	Unknown
hsa-miR-208a	MIMAT0000241	0.3711	CHD9, EIF4G2, PDCD4, FNIP1, FNIP2
hsa-miR-2116	MIMAT0011160	0.3798	Unknown
hsa-miR-1321	MIMAT0005952	0.3845	KLK4, RASSF5, ABCG4, MTA2
hsa-miR-668	MIMAT0003881	0.3872	SKAP2, ATP6AP2, HOXB4, ID4, TOX3, SLC26A7
hsa-miR-1913	MIMAT0007888	0.3945	Unknown
hsa-miR-513a-5p	MIMAT0002877	0.4201	CSNK1G1, GLT8D3, EPS8, TNPO1
hsa-miR-24-1*	MIMAT0000079	0.4274	Unknown
hsa-miR-2115*	MIMAT0011159	0.4403	Unknown
hsa-miR-3686	MIMAT0018114	0.4413	Unknown
hsa-miR-1973	MIMAT0009448	0.4434	Unknown
hsa-miR-1284	MIMAT0005941	0.4463	TADA1L, MARK3, MARK1, ATP2B2
hsa-miR-3182	MIMAT0015062	0.4620	Unknown
hsa-miR-193b*	MIMAT0004767	0.4780	Unknown
hsa-miR-3667-5p	MIMAT0018089	0.4809	Unknown
hsa-miR-181a	MIMAT0000256	0.4831	PIP3AP, ATP2B2, HOXB5, HOXA11, ATP2A2
hsa-miR-3926	MIMAT0018201	0.4907	Unknown
hsa-miR-664	MIMAT0005949	0.4917	HS6ST3, TNFAIP1, CYBB, GPR180
hsa-miR-615-3p	MIMAT0003283	0.4942	C6orf154, VSTM2L, GRIA4, SHANK3

Normalized hybridization signal ratio of miRNAs in SKOV3/CIS to those in SKOV3. The normalized fluorescence intensity, which was less than the average intensity of negative controls or 3x SD of the intensity of the negative controls, indicated an unreliable signal value. Differentially expressed miRNAs with statistical significance were selected only if they were altered by at least 2-fold ( $P < 0.05$ ). Expression of miRNAs in SKOV3/CIS compared to SKOV3 was decreased by 2.02- to 8.23-fold. Predicted targets are listed with the help of PicTar and TargetScan.




Figure 2. Expression of GFP in SKOV3 and SKOV3/CIS cell lines (original magnification, x40). (A) SKOV3 cells were transfected with the plasmid labeled with GFP gene sequences. GFP expression was observed under a fluorescence microscope after 48 h of transfection (A-1, normal light; A-2, fluorescent light). (B) After 48 h of transfection, GFP expression in SKOV3/CIS was observed under a fluorescence microscope (B-1, normal light; B-2, fluorescent light).

control. As shown in Fig. 1A, the expression levels of miR-130a were on average 24.43-fold higher in SKOV3/CIS cell than in parental SKOV3 cell ( $P < 0.05$ ), which was concordant with the result of miRNA expression profiling. In addition, western blotting showed that the expression level of P-gp was very high in SKOV3/CIS and was absent in SKOV3 cells (Fig. 1B). Overall, these findings suggest that upregulation of miR-130a in SKOV3/CIS was related to MDR1/P-glycoprotein-mediated cisplatin resistance.

*Expression of GFP indicating the high efficiency of the liposome-mediated transfection system.* We constructed the plasmid labeled with GFP gene sequences to assess the efficiency of the Lipofectamine 2000-mediated transfection system of ovarian cancer cells. After 48 h of transfection, microphotographs of both cell lines were captured under a fluorescence microscope (Nikon Eclipse 80I, Japan). As presented in Fig. 2, nearly 80% of green fluorescence could be clearly observed and detected in the cytoplasm of each cell line, which indicated that the liposome-mediated transfection system in our experiment, could reach high efficiency.

*Transfection of miR-130a modulating MDR1 and P-gp expression in SKOV3 and SKOV3/CIS.* To further investigate whether miR-130a is associated with MDR1/P-gp-mediated drug resistance, we examined the MDR1 mRNA and P-gp expression using qRT-PCR and western blot analysis after transfection. As shown in Fig. 3, the expression of MDR1 mRNA was upregulated in cisplatin sensitive SKOV3 cells transfected with an miR-130a-mimic, while inhibiting miR-

130a expression could remarkably decreased MDR1 and P-gp expression in drug resistant SKOV3/CIS cell, compared to miR-negative control ( $P < 0.05$ ). Overall, these results might indicate that upregulation of miR-130a in ovarian cancer cells is likely associated with MDR1/P-glycoprotein-mediated drug resistance.

*Transfection of miR-130a regulating cisplatin sensitivity in SKOV3 and SKOV3/CIS cells.* *In vitro* drug sensitivity array analysis was carried out to validate the role of miR-130a in cisplatin resistance of ovarian cancer cells. After transfection with a miR-130a-mimic or -inhibitor or with miR-negative, SKOV3 and SKOV3/CIS cells were treated with increasing doses of cisplatin. Cell viability curves are shown in Fig. 4, through which the  $IC_{50}$  of each sample was calculated. We found that cisplatin sensitivity was decreased in SKOV3 cells transfected with the miR-130a-mimic, while downregulating miR-130a expression overcame cisplatin resistance in SKOV3/CIS cells.

## Discussion

Chemotherapy remains an essential component for the treatment of ovarian cancer. Although platinum-based combined therapy has a good initial response, development of multidrug resistance is a major obstacle to successful treatment, which leads to relapse and poor prognosis. Consequently, it is necessary to discover novel targeting specific molecules regulating drug resistance and to develop rational approaches for further therapies. In recent years, accumulating evidence of the role of

Table III. Fifty-four upregulated miRNAs in SKOV3/CIS cell lines and the putative targets.

miRNA ID	Accession no.	Fold-change	Predicted targets
hsa-miR-1290	MIMAT0005880	2.0220	STK17A, KCNAB1, CDKN2B, STK3, TPRG1, MTMR3
hsa-miR-3651	MIMAT0018071	2.0978	Unknown
hsa-miR-27a	MIMAT0000084	2.1093	PLK2, HIPK2, MAP3K7IP3, SLC6A1
hsa-miR-17	MIMAT0000070	2.1367	SCN1A, MAP3K2, ITGB8, CASP2, AEN, CASP7
hsa-let-7e	MIMAT0000066	2.1426	HMGA2, CASP3, MAP4K3, CDKNA1, CDCA8
hsa-let-7i	MIMAT0000415	2.2700	CDC34, TTLL4, CDC25A, HOAX1, CASP3
hsa-miR-378	MIMAT0000732	2.3502	CDC40, IPO9, COAS2, CDC25A, PPIA
hsa-miR-4284	MIMAT0016915	2.3612	Unknown
hsa-miR-133b	MIMAT0000770	2.3670	KIF3C, CDC2L5, ABCC1, RICTOR
hsa-miR-106a	MIMAT0000103	2.3823	SCN1A, CDKNA1, CASP2, BCL2L11
hsa-miR-148b	MIMAT0000759	2.3954	ATP6AP2, BCL2L11, ABCB7, CDC2L6, CDK5R1
hsa-miR-181d	MIMAT0002821	2.5323	Unknown
hsa-miR-29b	MIMAT0000100	2.5671	COL1A1, PTEN, PPIC, CASP7, CDK6
hsa-let-7c	MIMAT0000064	2.5717	HMGA2, CDC34, CDC25A, CASP3
hsa-miR-3175	MIMAT0015052	2.8417	Unknown
hsa-let-7g	MIMAT0000414	2.9314	HIC2, CDC34, TTLL4, CCND2, CDC25A
hsa-miR-30b	MIMAT0000420	3.0119	CELSR3, ADRB1
hsa-miR-92a	MIMAT0000092	3.1155	CD69, PIK3R3, AATK, HIPK1, BCL9
hsa-miR-4289	MIMAT0016920	3.1368	Unknown
hsa-miR-23a	MIMAT0000078	3.4013	APAF1, CASP7, MAP4, CDC40
hsa-miR-744	MIMAT0004945	3.5532	KLC2, LRP3, PPPIA3
hsa-miR-320d	MIMAT0006764	3.6503	CDK6, TRIAP1, CAPRIN1, CDC2L5
hsa-miR-3653	MIMAT0004955	3.6628	Unknown
hsa-miR-320a	MIMAT0000510	3.6906	CDK6, TRIAP1, CAPRIN1, CDC2L5
hsa-miR-99a	MIMAT0000097	4.0488	THAP, TRAF7
hsa-miR-221	MIMAT0000278	4.2337	STK17B, CDKN1B, COAS2, CDC2L11, ABCC5
hsa-miR-15a	MIMAT0000068	4.2364	BCL2L2, CDC42, ABCC5
hsa-miR-365	MIMAT0000710	4.3053	SLC30A7, CDC25A
hsa-miR-98	MIMAT0000096	4.4196	CDC34, HMGA2, CDC25A, MAP4K3, CASP3, TTLL4
hsa-let-7d	MIMAT0000065	4.6394	HOXA1, CDC25A, TTLL4, ABCC10
hsa-let-7f	MIMAT0000067	4.7517	CDC25A, HOXA1, HOXA9
hsa-miR-130a	MIMAT0000425	4.8953	PTEN, GAX, HOXA, CSF1, CDC2L11, CDC2L6
hsa-miR-423-5p	MIMAT0004748	4.9183	CASP2, MAP1LC3A,
hsa-miR-374a	MIMAT0000727	5.5990	RAB22A, CCNL1
hsa-miRPlus-C1110	Unknown	5.8379	Unknown
hsa-miRPlus-A1015	Unknown	5.8735	Unknown
hsa-miR-26b	MIMAT0000083	5.9615	CDK6, THAP, PAWR, CCNL2, CDC6, MAP7, MARK1, MAP2, MAP1B
hsa-miR-20a	MIMAT0000075	6.0910	EIF5A2, MAP3K2, CDC40, CASP2
hsa-miR-25	MIMAT0000081	6.5038	CD69, BCL2L11, MOAP1, MARK1
hsa-miR-222	MIMAT0000279	6.8562	STK17B, CDKN1B, COAS2, CDC2L11, ABCC5
hsa-miR-30e	MIMAT0000692	7.2662	SCN2A, AVEN, CASP3, MAP6, BCL2L11
hsa-miR-320e	MIMAT0015072	7.6173	Unknown
hsa-miR-22	MIMAT0000077	7.7164	TET2, TP53INP1, CDK6, ESR1
hsa-miR-16	MIMAT0000069	8.2800	BCL2L2, CDC42, MAP7, CDCA4
hsa-miR-374b	MIMAT0004955	10.4786	STK38L, MAP2, ABCE1
hsa-miR-423-3p	MIMAT0001340	10.8543	PABPC1, BCORL1
hsa-miR-29a	MIMAT0000086	11.4590	MARK3, CASP7, MAP6
hsa-miR-19a	MIMAT0000073	11.6802	BCL2L11, ABCA1, CDC2L5, CDC10, MARK2

Table III. Continued.

miRNA ID	Accession no.	Fold-change	Predicted targets
hsa-miR-20b	MIMAT0001413	12.9075	CDC40, MASTL, CASP2, CASP7, MAPRE3
hsa-miR-331-3p	MIMAT0000760	15.1183	HOXC4, RGS6
hsa-miR-224	MIMAT0000281	16.5871	API5, HOXD4, CDK9, MAP1B
hsa-miR-106b	MIMAT0000680	17.7496	ITGB8, CASP2, EIF5A2
hsa-miR-3607-3p	MIMAT0017985	18.5386	Unknown
hsa-miR-15b	MIMAT0000417	46.7444	SCL11A2, CDCA4, MAP7, BCL2L2

Normalized hybridization signal ratio of miRNAs in SKOV3/CIS to those in SKOV3 cells. The normalized fluorescence intensity, which was less than the average intensity of negative controls or 3x SD intensity of negative controls, indicated an unreliable signal value. Differentially expressed miRNAs with statistical significance were selected only if they were altered by at least 2-fold ( $P < 0.05$ ). Expression of miRNAs in SKOV3/CIS compared to SKOV3 cells was increased by 2.02- to 46.74-fold. Predicted targets are listed with the help of PicTar and TargetScan.




Figure 3. Expression levels of MDR1 mRNA and P-gp in SKOV3 and SKOV3/CIS cells measured by qRT-PCR and western blotting respectively after transfection for 24 h. (A) Expression levels of MDR1 mRNA in SKOV3 and SKOV3/CIS after transfection with a miR-130a-mimic or -inhibitor or with miR-negative. Compared to the miR negative control, the expression of MDR1 mRNA was upregulated in SKOV3 cell transfected with miR-130a-mimic, while it was remarkably decreased in drug-resistant SKOV3/CIS cells transfected with the miR-130a-inhibitor ( $P < 0.05$ , compared to miR-negative control). (B) Expression levels of P-gp in SKOV3/CIS cells after transfection. Transfection with the miR-130a-inhibitor could downregulate P-gp expression in cisplatin-resistant SKOV3/CIS cells ( $P < 0.05$  compared to miR-negative control).

miRNAs in developing chemoresistance have been reported. Aberrant levels of miRNAs, including up- and downregulation, might modulate the expression of down-stream target proteins, which could be involved in several molecular

mechanisms of drug resistance. For instance, Kovalchuk *et al* (34) demonstrated that downregulation of miR-451 was associated with doxorubicin resistance in MCF-7 breast cancer cells by regulating P-gp expression. Another study




Figure 4. Cisplatin sensitivity is regulated by miR-130a in SKOV3 and SKOV3/CIS cells. (A) SKOV3 cells were transfected with miR-negative and miR-130a-mimic for 24 h. After transfection, SKOV3 cells were treated with increasing concentrations of cisplatin (0.3, 0.6, 1.2, 2.4, 4.8 and 9.6  $\mu\text{g/ml}$ ) for 48 h. Then the cellular viability was detected using the MTT assay. The  $\text{IC}_{50}$  of miR-negative and miR-130a-mimic was 0.935  $\mu\text{g/ml}$  vs. 1.756  $\mu\text{g/ml}$ . (B) SKOV3/CIS cells were transfected with miR-negative and miR-130a-inhibitor for 24 h. After transfection, SKOV3/CIS cells were exposed to increasing doses of cisplatin (3, 6, 12, 24, 48 and 96  $\mu\text{g/ml}$ ) for 48 h. Then the cellular viability was detected using the MTT assay.  $\text{IC}_{50}$  of miR-negative and miR-130a-inhibitor was 17.402  $\mu\text{g/ml}$  vs. 8.439  $\mu\text{g/ml}$ . Columns and bars represented the means and SE of three independent experiments. (\* $P < 0.05$ , \*\* $P < 0.05$ , compared to the miR-negative control).

reported that miR-15b and miR-16 could regulate multidrug resistance by targeting BCL-2 in human gastric cancer cells (35). Microarray, a high-throughput analysis, can be used to detect a genome-wide miRNA expression profiling and identify the appropriate candidates of aberrant miRNAs (36,37). Therefore, in the present study with the help of miRNA microarray platform, we have comprehensively isolated and analyzed a total of 1,289 human miRNAs between parental SKOV3 and cisplatin-resistant SKOV3/CIS cells, within which we discovered that 35 miRNAs were downregulated and 54 miRNAs were upregulated in the SKOV3/CIS cell line. Interestingly, some of these miRNAs and their downstream targets were previously reported to be involved in drug resistance of malignant cancer, such as miR-221/-222 targeting p27 (Kip1) in tamoxifen-resistant breast cancer (38); miR-27a targeting MDR1/P-gp in paclitaxel-resistant ovarian cancer (16); and miR-31 targeting E2F6 in prostate cancer cells (39). Consequently, these preliminary results, to the best of our knowledge, suggest that these differentially expressed miRNAs and predicted targeted proteins probably play a crucial role in the development of cisplatin resistance in ovarian cancer, which might provide novel insight for future approaches of gene therapies.

We verified the aberrant expression of miR-130a and performed a further investigation for the function of miR-130a in cisplatin resistance. Here, we found that upregulation of miR-130a might be associated with MDR1/P-glycoprotein-mediated drug resistance in SKOV3/CIS cells, while downregulating miR-130a expression might overcome cisplatin resistance. In recent studies, Wang *et al* (40) have reported that miR-130a expression is increased in non-small cell lung cancer (NSCLC) tissues, which was strongly associated with lymph node metastasis, stage of tumor node metastasis classification and poor prognosis. miR-130a has been reported to be a regulator in antagonizing the inhibitory effects of GAX on endothelial cell proliferation, migration and tube formation, and antagonizing the inhibitory effects of HOXA5 on tube formation *in vitro* (41). In addition, miR-130a has also been found to be

upregulated in MCF-7/ADR breast cancer cells (42). Thereby, we hypothesized that miR-130a acts as an oncogene, which could not only promote angiogenesis, metastasis and growth of cancer cells but also induce multidrug resistance to anticancer chemotherapeutics.

It has been reported that the phosphatidylinositol-3-kinase controlled signal transduction cascade (PI3K/Akt/PTEN/mTOR pathway) and the activity of drug transporters of the ABC superfamily (P-glycoprotein, MRP1, BCRP) were implicated in resistance of tumor cells to anticancer drugs (8,9,43). With the help of TargetScan, the phosphatase and tensin homolog (PTEN) gene was predicted to be a tumor suppressor and a potential target of miR-130a. Furthermore, our results indicate that miR-130a could modulate the expression levels of MDR1 mRNA and P-gp. A recent study showed that at least two mechanisms of drug resistance are interrelated in prostate cancer cells. PTEN and mTOR signaling were shown to be involved in the regulation of MRP1 and BCRP (44). Consequently, we assumed that miR-130a, acting as an intermediate, might regulate cisplatin resistance by activating PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporter pathways in ovarian cancer cells, which means that different mechanisms involved in drug resistance are probably interconnected.

In summary, we identified the differentially expressed miRNAs in SKOV3 and SKOV3/CIS cells, which suggested that these miRNAs and predicted targeted proteins probably play a crucial role in the development of cisplatin resistance in ovarian cancer. Moreover, we found that upregulation of miR-130a might be associated with MDR1/P-gp-mediated drug resistance in SKOV3/CIS cells and played the role of an intermediate in drug-resistance pathways in PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in ovarian cancer cells. More efforts are needed to further delineate the biofunctional roles of these miRNAs and relevant signaling pathways, which have significant implications in the development of targeted gene therapy for reversing cisplatin resistance in ovarian cancer.

## Acknowledgements

We are sincerely grateful to Professor Zhao Xia and Manager Yi Tao (Gynecological Oncology of Biotherapy Laboratory, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University) for experimental assistance. This study was supported by the Program for Changjiang Scholars and the Innovative Research Team (PCSIRT) in University (IRT0935) and the local Foundation of Science and Technology Department of Sichuan Province (no. 2009S20161).

## References

- Legge F, Ferrandina G, Salutati V, *et al*: Biological characterization of ovarian cancer: prognostic and therapeutic implications. *Ann Oncol* 16: 95-101, 2005.
- Heintz AP, Odicino F, Maisonneuve P, *et al*: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet* 95: S161-S192, 2006.
- Du Bois A and Pfisterer J: Future options for first-line therapy of advanced ovarian cancer. *Int J Gynecol Cancer* 15: 42-50, 2005.
- Foster T, Brown TM, Chang J, *et al*: A review of the current evidence for maintenance therapy in ovarian cancer. *Gynecol Oncol* 115: 290-301, 2009.
- de Jongh FE, de Wit R, Verweij J, *et al*: Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. *Eur J Cancer* 38: 2005-2013, 2002.
- Muggia F: Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. *Gynecol Oncol* 112: 275-281, 2009.
- Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat Rev* 33: 9-23, 2007.
- Hu M, Liu Y, Deng C, Han R, *et al*: Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. *Leuk Lymphoma* 52: 1302-1311, 2011.
- Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. *FEBS Lett* 580: 998-1009, 2006.
- Park E, Gang EJ, Hsieh YT, *et al*: Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. *Blood* 118: 2191-2199, 2011.
- Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. *Int J Cancer* 122: 534-546, 2008.
- Cheung CH, Wu SY, Lee TR, *et al*: Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. *PLoS One* 5: e12564, 2010.
- Zindy P, Bergé Y, Allal B, *et al*: Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. *Cancer Res* 71: 4068-4073, 2011.
- Sabatino MA, Marabese M, Ganzinelli M, *et al*: Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. *Mol Cancer* 9: 259, 2010.
- Kirschner K and Melton DW: Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. *Anticancer Res* 30: 3223-3232, 2010.
- Li Z, Hu S, Wang J, Cai J, *et al*: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. *Gynecol Oncol* 119: 125-130, 2010.
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
- Denli AM, Tops BB, Plasterk RH, *et al*: Processing of primary microRNAs by the Microprocessor complex. *Nature* 432: 231-235, 2004.
- Berezikov E, Guryev V, van de Belt J, *et al*: Phylogenetic shadowing and computational identification of human microRNA genes. *Cell* 120: 21-24, 2005.
- Lund E, Güttinger S, Calado A, *et al*: Nuclear export of microRNA precursors. *Science* 303: 95-98, 2004.
- He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5: 522-531, 2004.
- Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. *Dev Cell* 11: 441-450, 2006.
- Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. *Nat Rev Cancer* 6: 259-269, 2006.
- Iorio MV, Visone R, Di Leva G, *et al*: MicroRNA signatures in human ovarian cancer. *Cancer Res* 67: 8699-8707, 2007.
- Yanaihara N, Caplen N, Bowman E, *et al*: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 9: 189-198, 2006.
- Calin GA, Dumitru CD, Shimizu M, *et al*: Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 99: 15524-15529, 2002.
- Gong C, Yao Y, Wang Y, *et al*: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. *J Biol Chem* 286: 19127-19137, 2011.
- Hwang JH, Voortman J, Giovannetti E, *et al*: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. *PLoS One* 5: e10630, 2010.
- Tomimaru Y, Eguchi H, Nagano H, *et al*: MicroRNA-21 induces resistance to the anti-tumour effect of interferon- $\alpha$ /5-fluorouracil in hepatocellular carcinoma cells. *Br J Cancer* 103: 1617-1626, 2010.
- Krek A, Grün D, Poy MN, *et al*: Combinatorial microRNA target predictions. *Nat Genet* 37: 495-500, 2005.
- Grün D, Wang YL, Langenberger D, *et al*: microRNA target predictions across seven *Drosophila* species and comparison to mammalian targets. *PLoS Comput Biol* 1: e13, 2005.
- Lewis BP, Shih IH, Jones-Rhoades MW, *et al*: Prediction of mammalian microRNA targets. *Cell* 115: 787-798, 2003.
- Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120: 15-20, 2005.
- Kovalchuk O, Filkowski J, Meservy J, *et al*: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther* 7: 2152-2159, 2008.
- Xia L, Zhang D, Du R, *et al*: MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. *Int J Cancer* 123: 372-379, 2008.
- Lu J, Getz G, Miska EA, *et al*: MicroRNA expression profiles classify human cancers. *Nature* 435: 834-838, 2005.
- Pallante P, Visone R, Ferracin M, *et al*: MicroRNA deregulation in human thyroid papillary carcinomas. *Endocr Relat Cancer* 13: 497-508, 2006.
- Miller TE, Ghoshal K, Ramaswamy B, *et al*: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem* 283: 29897-29903, 2008.
- Bhatnagar N, Li X, Padi SK, *et al*: Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. *Cell Death Dis* 1: e105, 2010.
- Wang XC, Tian LL, Wu HL, *et al*: Expression of miRNA-130a in nonsmall cell lung cancer. *Am J Med Sci* 340: 385-388, 2010.
- Chen Y and Gorski DH: Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood* 111: 1217-1226, 2008.
- Cui XY, Guo YJ and Yao HR: Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR. *Nan Fang Yi Ke Da Xue Xue Bao* 28: 1813-1815, 2008 (In Chinese).
- Naumann RW: The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. *Gynecol Oncol* 123: 411-420, 2011.
- Sherbakova EA, Stromskaia TP, Rybalkina Elu, *et al*: Role of PTEN protein in multidrug resistance of prostate cancer cells. *Mol Biol (Mosk)* 42: 487-493, 2008 (In Russian).